In recent years, TIM-3 has emerged as a promising target for cancer immunotherapy, and anti-TIM-3 therapies are being explored as a means of reversing T-cell exhaustion and restoring antitumor immunity (32, 34, 35). This evidence concerns the gene HAVCR2 and cancer.